- Home
- FLUX vs ENTX Comparison
FLUX vs ENTX Comparison
Compare FLUX & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUX
- ENTX
- Stock Information
- Founded
- FLUX N/A
- ENTX 2010
- Country
- FLUX United States
- ENTX Israel
- Employees
- FLUX N/A
- ENTX N/A
- Industry
- FLUX Industrial Machinery/Components
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLUX Miscellaneous
- ENTX Health Care
- Exchange
- FLUX Nasdaq
- ENTX Nasdaq
- Market Cap
- FLUX 98.5M
- ENTX 106.4M
- IPO Year
- FLUX N/A
- ENTX 2018
- Fundamental
- Price
- FLUX $2.37
- ENTX $2.91
- Analyst Decision
- FLUX Strong Buy
- ENTX Strong Buy
- Analyst Count
- FLUX 2
- ENTX 1
- Target Price
- FLUX $6.00
- ENTX $10.00
- AVG Volume (30 Days)
- FLUX 989.0K
- ENTX 309.2K
- Earning Date
- FLUX 09-16-2025
- ENTX 11-07-2025
- Dividend Yield
- FLUX N/A
- ENTX N/A
- EPS Growth
- FLUX N/A
- ENTX N/A
- EPS
- FLUX N/A
- ENTX N/A
- Revenue
- FLUX $66,434,000.00
- ENTX $166,000.00
- Revenue This Year
- FLUX $8.23
- ENTX N/A
- Revenue Next Year
- FLUX $24.72
- ENTX N/A
- P/E Ratio
- FLUX N/A
- ENTX N/A
- Revenue Growth
- FLUX 9.22
- ENTX 191.23
- 52 Week Low
- FLUX $1.15
- ENTX $1.50
- 52 Week High
- FLUX $7.55
- ENTX $2.95
- Technical
- Relative Strength Index (RSI)
- FLUX 33.10
- ENTX 70.88
- Support Level
- FLUX $5.06
- ENTX $2.12
- Resistance Level
- FLUX $7.55
- ENTX $2.43
- Average True Range (ATR)
- FLUX 0.93
- ENTX 0.21
- MACD
- FLUX -0.49
- ENTX 0.04
- Stochastic Oscillator
- FLUX 2.45
- ENTX 97.53
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.